---
title: "Bionano Genomics IncQ) expected to post a loss of $6.00 a share - Earnings Preview"
description: "Bionano Genomics IncQ) is anticipated to report a loss of $6.00 per share and a 42.2% decline in quarterly revenue, dropping to $6.2 million from $10.72 million year-over-year. The company's guidance "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/233691344.md"
published_at: "2025-03-28T20:52:06.000Z"
---

# Bionano Genomics IncQ) expected to post a loss of $6.00 a share - Earnings Preview

> Bionano Genomics IncQ) is anticipated to report a loss of $6.00 per share and a 42.2% decline in quarterly revenue, dropping to $6.2 million from $10.72 million year-over-year. The company's guidance for revenue was between $7.90 million and $8.10 million. Analysts maintain a "hold" rating with no strong buy recommendations, and the median 12-month price target is $60.00, significantly higher than its last closing price of $3.07.

-   Bionano Genomics Inc (BNGO.OQ) (BNGO.O) is expected to show a fall in quarterly revenue when it reports results on March 31 for the period ending December 31 2024
    
-   The San Diego California-based company is expected to report a 42.2% decrease in revenue to $6.2 million from $10.72 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company’s guidance on January 13 2025, for the period ended December 31, was for revenue between $7.90 million and $8.10 million.
    
-   ​LSEG’s mean analyst estimate for Bionano Genomics Inc is for a loss of $6.00 per share.
    
-   The current average analyst rating on the shares is “hold” and the breakdown of recommendations is no “strong buy” or “buy,” 2 “hold” and no “sell” or “strong sell.”
    
-   The mean earnings estimate of analysts was unchanged in the last three months. ​
    
-   Wall Street’s median 12-month price target for Bionano Genomics Inc is $60.00​, above​ its last closing price of $3.07. ​​​ This summary was machine generated March 28 at 20:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

### Related Stocks

- [BNGO.US - Bionano Genomics](https://longbridge.com/en/quote/BNGO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Epstein Funded UCSD Study Of 'Telepathic Autistic Savant' Through Deepak Chopra Connection | Jeffrey Epstein funded a UC San Diego lab studying an 'autistic savant who displays telepathy' after being introduced to | [Link](https://longbridge.com/en/news/276356049.md) |
| 06:05 ETFranklin Law PC: San Diego Jury Awards $2.335 Million Verdict in Employment-Related Dispute | A San Diego jury awarded $2.335 million to Edgar Figueroa after finding Sullivan Properties, Inc. discriminated against  | [Link](https://longbridge.com/en/news/276219160.md) |
| Lockheed Martin Stock: Analyst Estimates & Ratings | Lockheed Martin Stock: Analyst Estimates & Ratings | [Link](https://longbridge.com/en/news/276134742.md) |
| New ‘Hello Kitty’ Comic Book Universe Set From Sanrio, IDW (EXCLUSIVE) | New “Hello Kitty” comic books will soon launch as part of a collaboration between Japan’s Sanrio and comics giant IDW Pu | [Link](https://longbridge.com/en/news/276394257.md) |
| Mike's Red Tacos Launches National Franchising Initiative with 200+ Locations Under Development | Mike's Red Tacos, a popular San Diego Birria restaurant, has launched a national franchising initiative with over 200 lo | [Link](https://longbridge.com/en/news/276149504.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.